FDA Approves First-in-Class Centanafadine for Treatment of ADHD

FDA approved centanafadine (Simtriyo), the first NDSRI CNS stimulant for ADHD in patients aged 6+ years, following phase 3 trials showing statistically significant symptom improvement with effects emerging by week 1. The drug carries boxed warnings for suicidal ideation in children and abuse/addiction potential, with commercial availability expected after DEA scheduling.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.